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Migraine is a common neurovascular disorder affecting ∼15% of the general population.
Ranking second in the list of years lived with disability (YLD), people living with migraine
are greatly impacted by this especially burdensome primary headache disorder. In
∼30% of individuals with migraine, transient neurological symptoms occur (migraine
aura) that further increase migraine burden. However, migraine burden is differential
with respect to sex. Though one-year prevalences in childhood are similar, starting with
puberty, migraine incidence increases at a much higher rate in females than males.
Thus, migraine over the life course occurs in women three to four times more often
than in men. Attacks are also more severe in women, leading to greater disability and
a longer recovery period. The sex disparity in migraine is believed to be partly mediated
through fluctuations in ovarian steroid hormones, especially estrogen and progesterone,
although the exact mechanisms are not yet completely understood. The release of
the neuropeptide calcitonin gene-related peptide (CGRP), followed by activation of the
trigeminovascular system, is thought to play a key role in the migraine pathophysiology.
Given the burden of migraine and its disproportionate distribution, the underlying cause(s)
for the observed differences between sexes in the incidence, frequency, and intensity of
migraine attacks must be better understood. Relevant biological as well as behavioral
differences must be taken into account. To evaluate the scope of the existing knowledge
on the issue of biological sex as well as gender differences in migraine, we conducted a
systematized review of the currently available research. The review seeks to harmonize
existing knowledge on the topic across the domains of biological/preclinical, clinical, and
population-level research, which are traditionally synthesized and interpreted in isolation.
Ultimately, we identify knowledge gaps and set priorities for further interdisciplinary and
informed research on sex and gender differences as well as gender-specific therapies
in migraine.
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INTRODUCTION
Migraine is a common neurovascular disorder in the general
population (1), estimated to affect 1.3 billion [95% uncertainty
interval (UI) 1.2–1.4] people, corresponding to a global all-age
point prevalence of 18.0% (2).
Migraine attack severity and frequency can vary over time and
lead to different degrees of disability (3). Thus, globally, migraine
accounts for 47.2 million (95% UI 30.0–68.7) years of life lived
with disability (YLDs) (2). It ranks second in YLD among all
causes of disability defined by the Global Burden of Disease study
(GBD), and its burden is not localized to specific GBD regions but
is globally distributed (4).
Migraine has a transient nature and is described by the
International Classification of Headache Disorders (ICHD) as a
primary headache disorder with recurrent unilateral headaches.
Two major types of migraine are distinguished: migraine with
aura and migraine without aura. In both types, the headache
attacks last 4–72 h, are pulsating, and can be accompanied by
nausea, photophobia, and/or phonophobia. Migraine with aura
additionally presents with unilateral and fully reversible central
nervous system symptoms (1).
The prevalence of migraine in women is higher than in
men (2), and sex hormones are believed to play a key role in
this discrepancy (5). After all, in females of childbearing age,
migraine accounts for 11.2% of total YLDs (4). Sex hormones,
especially fluctuations of estrogen and progesterone, are believed
to impact the pathogenesis of migraine (6). Brain magnetic
resonance imaging (MRI) studies have confirmed structural as
well as functional differences between males and females with
migraine (7).
Animal studies have further confirmed differences with
respect to sex hormones implicated in migraine between male
and female rats (8, 9), however, the majority of animal studies
have been performed in male animals (5, 10). In contrast, male
participants in clinical and population-based research studies on
migraine are largely lacking, and differences with respect to sex
and gender in people suffering from migraine have yet to be
rigorously addressed (11).
Despite considerable research activity in the field of migraine
over the last two decades (12), we still know little about the
underlying mechanisms of the development of migraine (13).
Previous reviews have provided extensive narrative overviews
of the available evidence regarding sex differences in migraine,
considering both preclinical/biological as well as clinical aspects
(11, 14, 15). However, a systematized search of the literature, to
our knowledge, has not yet been conducted. This review aims
to synthesize new evidence on sex and gender differences in
migraine (published within the last 5 years). Using a systematized
review approach to synthesize findings from different research
fields, we attempted to provide a transparent and complete
overview of recent relevant literature.
Furthermore, we aimed to identify areas of particular promise
for future exploration and use interdisciplinary, translational
knowledge to fill gaps in the individual subdomains of migraine
research. Based on this comprehensive overview, we provide
researchers with recommendations for further research in
this field.
METHODS
We conducted a systematized review of the scientific literature
concerning gender- and sex aspects of migraine in adults.
We searched four databases: Embase, Medline (Ovid), Web-
of-Science (Core Collection) and Google Scholar for relevant
articles published between 01-01-2015 and 18-12-2019. Since
we identified multiple earlier narrative reviews on the topic,
we focused on the synthesis of newly published findings in
an effort to avoid unnecessary overlap with previous reviews
and to build directly upon these findings. Only scientific
articles (including reviews) presenting sex- and/or gender-
specific findings in original migraine research were considered
for inclusion. We excluded articles limited to estimating well-
described incidence and prevalence differences of migraine in
men and women in various settings. We further excluded
articles that were not focused on sex- or gender- specific aspects
but had restricted study populations composed of only one
specific sex or gender group. An exception was made for articles
describing studies pertaining to women’s biological health (e.g.,
menstruation, pregnancy and menopause), as new findings in
this area are crucial to facilitate a better understanding of these
sex differences.
Additionally, since this review focuses on migraine in
adults, we did not include articles exclusively reporting findings
on children or adolescents (aged <18 years), except for
articles concerningmenstruation ormenarche. Moreover, studies
investigating consequences and comorbidities of migraine, as
well as those assessing efficacy and effectiveness of specific
treatments and therapies were not included.We further restricted
study eligibility to include articles available in English and as
full-text manuscripts. We also excluded case reports and case
series, book chapters, news articles, conference abstracts or other
contributions, and dissertations.
The search strings used in the different databases included
known synonyms of migraine and sex/gender terminology
to maximize the sensitivity of the search. We used the
following terms to conduct the literature search: “migraine,”
“primary headache,” “sex characteristics,” “sex factors,” “gender
identity,” “hormone,∗” “intersex,∗” “gender,∗” “transgender,∗”
“hermaphrod,∗” “female,∗” “woman,∗” “women,” “male,” “man,”
“men,” “sex,” “sexual,” “sexes,” and “dimorphism.” The specific
search strings can be found in the Supplementary.
We conducted the search on December 18th, 2019.
Manuscripts were excluded during full-text screening for
the following reasons: articles limited to prevalence, no gender-
specific aspects, articles limited to one sex/gender or not
reporting differences/similarities, averaging of effects across
sex/gender groups (e.g., through matching on sex/gender),
studies focused on comorbidities, testing of specific migraine
treatments, no full-text accessible, text was part of a book
chapter, and previously unidentified duplicates. After full-text
screening, included articles were categorized into five domains
including: basic science, epidemiology, clinical science, genetics
and neuroimaging, for synthesis.
Contrary to previous works, we placed a particular emphasis
on including (trans)gender and sex aspects - hormonal,
behavioral, cultural as well as psychological traits - of migraine,
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which may provide important biological mechanistic insights.
So far, a strong focus has been placed on sex differences,
however, we believe that gender aspects might also play
an important role in explaining the uneven distribution of
migraine. Thus, we included both sex and gender aspects in
this review. In this review, we define “sex” as referring to
biological differences, concerning hormones, chromosomes, and
sex organs, whereas we consider “gender” to refer to a social
construct, encompassing enacted roles and behaviors, which are
shaped by cultures and can change over time (16, 17). We
believe both sex and gender are important determinants of
health (18).
We acknowledge that modern definitions of sex and gender go
beyond the binary in an effort to include individuals such as those
identifying as intersex, transgender, genderfluid or genderqueer.
Although such non-binary definitions are largely absent in the
migraine literature, they have been captured as comprehensively
as possible in this review. In our approach, we sought to identify
important areas with some scientific consensus about sex and
gender differences in migraine research.
RESULTS
Running the search strategy resulted in 1,901 unique retrieved
articles after deduplication. Two reviewers (LAH and JH)
independently screened the titles and abstracts of all retrieved
articles for inclusion based on the prespecified eligibility criteria.
After the first screening, there was initial agreement on inclusion
of 67 articles and an additional 113 articles after discussion. For
15 articles, no consensus was found, and a third independent
reviewer (JLR) was consulted to determine which of these were
eligible. In total, 120 articles were eligible for full-text screening.
After the second screening stage, 79 out of the 120 articles were
ultimately selected for inclusion in the review. Figure 1 shows
the flowchart of the review process, which was modified from
PRISMA 2009 Flow Diagram (19).
Epidemiology
In 2017, the global point prevalence of migraine was estimated
to be 18.1% (95% UI 16.8–19.4), affecting ∼1.3 billion (95% UI
1.2–1.4) people globally (2). Migraine is reported to be two-to-
three times more prevalent in women than in men (11, 14) and
have a 3- to 4-fold prevalence in women after puberty compared
to men (20). This equates to a point prevalence of 22.6% (95% UI
21.1–24.3) in females and 13.5% (95% UI 12.5–14.5) in males in
2017 (2). One-year migraine attack prevalence estimates indicate
active migraine in 18% of females and 6% of males globally,
whereas the cumulative incidences over the lifetime are 43% and
18% respectively (11, 14, 21). The prevalence ratio between males
and females does not stay constant but varies with age (11, 14, 22).
The largest 1-year prevalence ratio between sexes can be observed
at 30.2 years of age (11, 23).
There is a tendency of earlier onset of migraine in boys (22).
The infantile migraine prevalence is similar for boys and girls,
with both showing an increase beginning during puberty (11).
However, this increase is steeper in women (11). According to
the 2017 data, the migraine point prevalence peaks for both
sexes between ages 35–39 reaching 34.5% (95% UI 29.9–39.3)
and 20.3% (95% UI 17.5–27.2), respectively (2). Tonini suggests
that active migraine prevalence follows a bimodal pattern with
peaks around the age of 35 years and 50 years (20). However,
the latest GBD data from 2017 do not show this second peak in
this age group (2). In women, active migraine tends to decrease
after menopausal transition (11, 14). In contrast with prevalent
migraine, the peak in migraine incidence can already be observed
during the age range of 20–24 years in women and 15–19 years in
men (2, 11).
The global burden of migraine is indicated by the high rate
of 618.4 (95% UI 392.5–898.8) years lived with disability (YLDs)
per 100,000 people (2). From the latest reports in 2016, migraine
ranked second among diseases leading to YLDs globally and
accounted for 5.6% of YLDs globally (4). Migraine is described
as particularly burdensome among middle-aged women (4). In
general, migraine accounts for 6.6% (95% UI 4.6–8.7) of YLDs in
women and 4.4% (95% UI 3.0–6.1) in men (2). A cross-sectional
survey using a time trade-off approach found that men attribute
lower health state utilities to migraine conditions compared to
women (24). Especially from a life course perspective, these
utilities were found to be significantly different between males
and females (24). In this study, health state utilities were
determined by howmuch of their remaining lifetime participants
would be willing to sacrifice for a migraine free health
state (24).
Migraine studies clearly demonstrate the impact of the
disease on everyday life. A cross-sectional survey about
family, relationship, career, educational, and financial aspects
in migraine patients showed that overall, males and females
were similarly affected in many areas (25). Gender differences
were observed in that men indicated to worry more about
migraine compromising their careers than women. However,
migraine appeared to actually have a greater impact on women’s
careers compared to men’s (25). Moreover, compared to men,
women more often indicated they would have better overall
health and less stress without migraine (25). The cross-sectional
study from Brazil showed that both men and women with
migraine reported more psychologically demanding jobs, less
freedom in decision making in their jobs, and less social support
at work (26). Especially among women, work conflicting with
family and leisure was significantly associated with migraine
activity (26). Furthermore, Hammond et al. found differences
in associations between migraine and marital status, with men
having higher odds of migraine in common-law relationships.
Among older women, divorced or separated females had the
highest odds of havingmigraine (27). Differences were also found
in sexual orientation; gay and bisexual men aged 45–85 had a
50% higher odds of ever having migraine, whereas lesbian and
bisexual women in the same age range had a 23% lower odds
compared to heterosexual men and women, respectively (27).
It was hypothesized that the underlying factor for the observed
increased odds among gay and bisexual men was minority stress
(27), however, to our knowledge, this has not yet been formally
investigated. Also in terms of ethnicity, higher odds for migraine
prevalence were observed in older non-white people compared to
older white people in both sexes (27).
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FIGURE 1 | Flowchart of the review process, modified from PRISMA 2009 Flow Diagram (19).
Conflicting results were found concerning education and
income. In a recent cross-sectional study, education and social
support were not associated with migraine (27). However, in
another cross sectional analysis of the EuropeanHealth Interview
Survey for Spain, it was found that migraine was more prevalent
in both men and women with lower education and income
levels (28). Among older women, a social gradient was observed,
with a 3% (95% CI 0.96–1.01) decrease in the odds of migraine
with increasing social status, whereas in men aged 45–85 years,
migraine was associated with economic status (27).
Certain kinds of physical activity were found to be associated
with lower odds of having migraine, but only among older
women (27). Accordingly, another study found that both females
and males reporting low levels of physical activity had a higher
odds of having migraine (29). Additionally, hypertension and
consumption of light alcoholic beverages showed an association
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with migraine; however, consumption of strong alcoholic
beverages was not found to be associated with migraine (29).
Furthermore, associations between migraine and a history of
head trauma as well as family history of headache were found in
both women and men (29).
In general, migraine is characterized by a pattern of migraine
attacks, remission, and relapse, with men tending to have longer
remission periods than women (11, 20). Furthermore, headache
attack duration is reported to be longer in women experiencing
migraine attacks (20). Attack frequency and intensity seem
to be similar in males and females, but severe headaches
persist longer over the lifetime of women and are reported
to be more bothersome (20). Symptoms including photo-
and/or phonophobia, nausea, vomiting, and skin allodynia
occur more often in women with migraine attacks than in
men (20).
It remains unclear whether biological sex plays an important
role in the transition from episodic to chronic migraine
(11). In the Chronic Migraine Epidemiology and Outcomes
(CaMEO) study, no major differences were observed, however,
after adjusting for demographics, comorbidities, and headache
features, the odds for such a transition was 43% higher for men
compared to women (30).
Concerning the subtypes, migraine without aura is more
common in both sexes (11). The remission rate appears
unaffected by migraine subtype, with a cohort study showing that
46% were free of active migraine by the age of 50 (11, 31).
Among women, there is another differentiation of migraine
subtypes based on menstruation, which distinguishes pure
menstrual migraine, menstrually related migraine and non-
menstrual migraine (32).
A cohort study by Scher et al. (30) found that 56.5% of
males and 68.6% of females identified individual trigger factors
for their migraine. While triggers including “hunger/skipping
meals, thirst/dehydration, flashing/bright lights, extended screen
exposure, neck strain, change in sleep patterns, caffeine [or lack
of it], certain foods, [and] changes in weather/temperature” were
more often reported by women, men reported common triggers
to include “strong odors/scents and stress/stressful times” (30).
Furthermore, in women, the time around menses, before and
after onset, was often reported as a trigger factor (32).
Basic Science and Preclinical Research
Sex Aspects
As the pathophysiological mechanism of migraine is complicated
and involves a variety of interrelated neurological and vascular
processes, we highlight the most important developments in
basic research related to sex differences. It is important to realize
that several aspects involved in the pathophysiology of migraine
may interact with each other, and thus the topics below are
tightly interrelated.
Central mechanisms
Previous research has shown that migraine auras might be caused
by cortical spreading depression (CSD), which is a propagating
wave of initial depolarization of neuronal and glial cells followed
by prolonged depression (33, 34). Although not all migraine
auras are followed or accompanied by headache pain (typical aura
without headache), trigeminovascular activation induced by CSD
may be, at least in part, responsible for the migrainous headache.
Ovarian hormones have been linked to CSD susceptibility (10, 14,
15, 35, 36).
Low serotonin (5-HT) levels and reduced brain serotonin
synthesis have also been linked to migraine (37). Serotonin
(5-HT) is synthesized from tryptophan, which is transformed
into 5-hydroxytryptophan (5-HTP) via the enzyme tryptophan
hydroxylase (TPH). Estrogen is able to influence enzymes
at different stages of the metabolism of tryptophan. Chauvel
et al. explored the interrelations between serotonin, cortical
excitability, and sex hormones in female and male rats. Their
findings confirm that: (a) elevated estrogen levels increase
cortical excitability, while estrogen withdrawal decreases CSD
and normalizes it, (b) 5-HTP decreases the occurrence of
CSD, but only in the presence of ovarian hormones and (c)
in oophorectomized rats that received estradiol replacement,
increased CSD was observed, which decreased after estradiol
withdrawal (38).
The observed results from animal models might offer an
explanation for the clinically observed association between
attacks with aura and stable, high estrogen levels (e.g., during
pregnancy or intake of the combined contraceptive pill).
Following this line of reasoning, it seems feasible that the
majority of menstrually related migraine attacks, due to estrogen
withdrawal, tend to occur without aura (38).
Familial hemiplegic migraine. Other studies reported results
from animal models of familial hemiplegic migraine type 2
(FHM2). FHM2 is a rare subtype of migraine with aura caused
by mutations in the ATP1A2 gene, which encodes the α2 subunit
of the Na+/K+ pump (39). This altered ion homeostasis leads to
a disturbance of the sodium homeostasis (40).
An included article supported the hypothesis that estrogen
plays an important role in the glutamate system in the brain (and
blood). The introduction of a new α2Na+/K+-ATPase knock-
in (KI) mouse model (α2+/G301R) showed that male mutated
mice have a prolonged recovery phase after induction of CSD
compared to wild type mice. Also, a link between the female sex
hormone cycle and the glutamate system was established. Female
α2+/G301R mice showed female-specific behaviors, including
hypolocomotion and reduced motor skill learning/coordination.
These effects were rescued after treatment with Depoprovera,
a progestin-only contraceptive, which leads to stabilized and
low estrogen levels. Lastly, it was observed that the uptake
function of glutamate was affected and that glutamate levels
were increased in lysates from various female brain regions
in mice (41).
Krost et al. also experimented with the aforementioned
α2+/G301R mouse model. The experiments showed increased
susceptibility to CSD in α2+/G301R mice; however, the results did
not show sex-based effect of this increased susceptibility in adult
and aged female mice compared to female mice. Nevertheless,
these results suggest that this effect might be present during a
restricted period of the menstrual cycle. The authors also found a
decreased susceptibility to CSD after menopause in female mice
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but not with age in male mice, indicating an age-associated shift
toward CSD (42).
We recommend a prior review by Dehghani and Karatas
(43) concerning the use of FMH mouse models for more
details on the study of sex differences in pathophysiological
(including neurophysiological and behavioral) mechanisms
involved in migraine.
Nociception-related proteins. Studies have demonstrated that
estradiol receptors are located in trigeminal nociceptors.
Therefore, the binding of estradiol might lead to the activation
of extracellular signal-regulated kinase (ERK) and an increase of
nociception (44).
To study the role of estrogen in the pathogenesis of
migraine, Vermeer et al. utilized a multibehavioral model of
migraine in rats and investigated responses to the exposure
of estrogen. As compared to vehicle treatment, estradiol
treatment led to a statistically significant decrease in locomotor
activity as well as significant light and noise avoidance,
allodynia-associated behaviors, and an enhanced acoustic startle.
Moreover, estradiol treatment led to an increased expression
of genes associated with estradiol signaling (expression of
estrogen receptors), inflammation, vasodilation, and endogenous
cannabinoid metabolism. Lastly, this treatment led to the
activation of the nociception-related ERK (45).
Guo et al. investigated the role of the expression of proteins
involved in the transmission of nociceptive signals, including
brain-derived neurotrophic factor (BDNF) and its receptor,
tropomyosin receptor kinases (TrkB), as well as ERK and its
downstream target, cAMP-responsive element binding protein
(CREB), in migraine by using injections of nitroglycerin to
provoke migraine in rats. A positive relationship between the
BDNF/TrkB and ERK/CREB pathways and the contribution
of estrogen was observed. Indeed, female ovariectomized rats
showed a significant decrease in the expression of BDNF, TrkB, p-
CREB, and p-ERK in migraine attacks and intervals compared to
rats with intact ovaries. However, the administration of estrogen
recovered the expression in these ovariectomized rats. Moreover,
researchers observed higher serum levels of BDNF in female than
in male rats during migraine attacks (46).
Peripheral mechanisms
Dysregulation of neuropeptides. Animal studies have provided
important insights into the influences of calcitonin gene-related
peptide (CGRP) in migraine. This neuropeptide is thought
to play a pivotal role in the pathophysiology of migraine,
as it contributes to trigeminal nerve hypersensitivity and
photosensitivity (47, 48). Avona et al. recently reported a female-
specific response to dural administration of CGRP in a rodent
migraine model assessing cutaneous periorbital hypersensitivity
(49). Specifically, female rats and mice responded to lower
doses of dural CGRP than their male counterparts. The authors
concluded that female sex hormones have the ability to increase
vasodilation in response to CGRP; however, the anatomical and
physiological mechanisms explaining this difference in response
have yet to be elucidated (49).
Pro- and anti-inflammatory mediators. Compelling evidence
has been published in support of the theory that migraine is
associated with a sterile inflammation of the dura, leading to
increased pro-inflammatory cytokines and chemokines in plasma
and cerebrospinal fluid during attacks (50–52). McIlvried et al.
hypothesized that stress, being a triggering factor in migraine,
induces a shift in the balance of pro- and anti-inflammatory
mediator expression in dural lymphoid cells toward those that
trigger a migraine attack. Moreover, they hypothesized that this
effect is larger in females and that it is (partly) dependent
on sympathetic postganglionic innervation of the dura. The
authors tested their hypothesis in adult male and female rats.
The results confirmed their hypothesis, as a sex difference was
observed in (a) the increase in pro-inflammatory mediators,
(b) decrease in anti-inflammatory mediators, and (c) expression
of some inflammatory mediators. Moreover, (d) sympathetic
postganglionic innervation only influenced the stress-induced
increase of pro-inflammatory mediators in females. This article
offers possibilities for different therapeutic targets in males and
females (53).
We also recommend the review by Loewendrof et al. for a
detailed overview of the role of mast cells, which are part of the
innate immune system, and sex hormones in migraine (54).
TRP channels. Other structures implicated in various sensorial
functions and in the pathophysiology of migraine include
the non-selective cation channels Transient Receptor Potential
(TRP) channels (55). Our search strategy included a review
which describes the role of gonadal hormones in the activation,
modulation, and regulation of the main thermoTRP channels in
migraine (56).
We additionally point readers to previously published reviews
from 2017 and 2018 focused on sex differences of migraine
in animal models for more detailed discussions (11, 14,
15). Lastly, we recommend a review by Loewendorf et al.
for a comprehensive and short summary of the literature
concerning themechanisms central sensitization, channelopathy,
and sodium homeostasis in migraine (54).
Gender Aspects
Obviously, gender aspects in laboratory animal studies are hard
to describe and might, if present at all, be mainly related to
behavioral aspects. However, investigation of sex differences in
animal behavior e.g., (41, 45), could be possibly interpreted as
studies on gender aspects. Indeed, the way pain is experienced
can be thought of as a behavioral aspect, although also sex
components definitely influence pain perception. Whereas it
is generally accepted in humans that pain is experienced
differently in men and women, understanding the motivation
behind certain behavioral traits in animals is impossible.
Descriptions of behaviors that reflect pain in animal studies
include avoidance responses and tending to the site of pain. It
is worth mentioning that behavioral aspects in animal studies are
consistent with human studies. Indeed, lower pain thresholds and
an increased need for opioids have been shown in females vs.
males (54).
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Translational Science: “From Bench to
Bedside”
Some articles combined basic research with research in the
clinical setting involving (migraine) patients, although they
generally described sex differences rather than gender differences.
These articles mainly aimed to describe the pathophysiology
of migraine.
A study by Karkhaneh et al. determined the effect of 17β-
estradiol on the expression and activity of genes involved in the
process of neurogenic inflammation. The authors studied the
regulation of CGRP expression, inducible nitric oxide synthase
(iNOS) activity, and NO and interleukin-1beta (IL-1β) release in
females with pure menstrual migraine and age-and sex-matched
healthy individuals. Cultured peripheral bloodmononuclear cells
from these participants were treated with 17β-estradiol both, at
physiological and pharmacological doses. The pharmacological
dose caused a significant increase in mRNA expression of CGRP
in both groups. In contrast, the physiological dose caused a
significant decrease in mRNA expression of CRP, CGRP protein
levels, IL-1β release, NO production and iNOS activity only in
females with pure menstrual migraine (57).
In a review article, Labastida-Ramírez et al. describe sex
differences of CGRP in migraine. This review highlights
the profound effects varying ovarian hormones have on the
trigeminovascular system in both animal and human migraine
preclinical research models (58).
Ibrahimi et al. measured dermal blood flow after topical
forearm application of capsaicin (the active component of
chili peppers) to study endogenous release of CGRP among a
group of migraine sufferers and individuals without migraine.
Unlike males, females without migraine showed changes in the
CGRP-dependent dermal blood flow response, which was also
elevated during menstruation compared to the late-secretory
phase. Females with migraine also had higher dermal blood
flow responses during both menstruation and the late-secretory
phase compared to females without migraine, suggesting an
interrelationship between the menstrual cycle, migraine, and
vascular effects mediated by CGRP (59).
Additionally, a comparable human model was developed for
application of capsaicin on forehead skin, which is a trigeminal
nerve–innervated dermatome, in order to study the effects of the
menstrual cycle. The underlying mechanism includes activation
of a TRP (TRPV1) channel by capsaicin, thereby enhancing
the release of CGRP. The authors did not detect changes in
trigeminovascular reactivity during the cycle in patients with
menstrually related migraine in contrast to females without
migraine (60).
Clinical Science
Our search strategy retrieved a variety of original articles
and reviews containing clinical evidence on the relationship
between migraine, sex, and gender. As these results cover an
extensive range of themes and research questions, we have
classified them into different categories for the sex aspect of
this review: sex hormones, reproductive events (occurring in
women), biomarkers, and additional topics - which might be
related to the pathophysiology of migraine. Clinical articles
concerning gender aspects have been described separately for
lifestyle factors, although it should be kept in mind that our two
main themes - sex and gender - contain overlapping aspects.
Sex Aspects
Sex hormones
The “estrogen withdrawal hypothesis” has been expanded by
several articles we included. Earlier studies consistently showed a
withdrawal of estrogen in the late luteal (or premenstrual) phase,
whereas the association between migraine and withdrawal of
estrogen in the follicular (or periovulatory) phase has been more
debated (61–64).
Pavlović et al. provide a possible explanation for the latter
and show the influences of the menstrual cycle phase and
timing (65). They compared the daily sex hormone levels and
within-women rates of change between females with a self-
reported history of migraine and controls aged 42–52 years. This
study showed significant differences in the decline of urinary
estrogen in the late luteal phase; individuals with migraine
showed a faster decline. However, no differences in the rate of
decline in the periovulatory phase and no significant differences
in the peak or mean daily levels of estrogen were observed
between individuals with migraine and controls. Lastly, they
found that in the migraine group, the rate of decline in
estrogen does not discriminate cycles with and without an acute
headache. Therefore, the authors hypothesize that rapid estrogen
withdrawal is not a direct trigger of migraine, but rather an
endogenous characteristic and a marker for neuroendocrine
vulnerability in females with migraine due to a disruption of the
trigeminovascular system. Also, as progesterone has modulatory
effects on estrogen in migraine, its rising levels may counteract
the effects of periovulatory estrogen decline (65).
Few studies were solely performed in a male study population
or attempted to investigate the role of sex hormones in this
underrepresented group. It is not clear whether sex hormones
modulate migraine susceptibility (risk and activity) in men as
they do in women. Moreover, the role of testosterone in migraine
is described in fewer studies than estrogen or progesterone.
A prospective study compared the levels and ratio of
sex hormone plasma (17β-estradiol and free testosterone) in
a group of medication-free, non-obese men with episodic
migraine (18–74 years) to males without migraine group-
matched for age and body mass index (BMI). In this study,
males with migraine exhibited elevated estradiol levels, both
absolute and relative to free testosterone, and showed clinical
evidence of functional androgen deficiency (66). A pilot study
investigated total serum testosterone levels in males aged 26–
51 years with chronic migraine. Men with chronic migraine
had lower total testosterone levels compared to an age-matched
normative population, suggesting abnormalities in the regulation
of the hypothalamus-pituitary-gonadal (HPG) axis (67). These
abnormalities were then confirmed by Li et al. considering the
levels of hormones. They found that levels of progesterone in
males and females with migraine in the postmenopausal phase
were lower compared to healthy controls. Also, they found
significantly higher levels of gonadotropin-releasing hormone
(GNRH) in males with migraine, in the follicular phase as well as
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the luteal phase in females with migraine, and in postmenopausal
females with migraine compared to controls (68).
As all three studies were limited by their small sample sizes,
larger studies are needed to replicate these findings and to
investigate whether hormone fluctuations (as well as testosterone
supplementation) might be associated with changes in migraine
activity and frequency.
Lastly, supporting the hypothesis that migraine should be seen
as a consequence of a loss of neurohormonal and metabolic
integrity instead of a primary disorder, Dzugan et al. reported
successfully treating difficult-to-treat males (n = 3) and females
(n = 27) with migraine and a mean age of 46.4 years.
Participants received therapy with bio-identical hormones to
restore hormonal levels. As part of the restoration of the integrity
between various systems (including the HPG axis) in order
to manage migraine, they postulate that serum levels of all
basic hormones (pregnenolone, dehydroepiandrosterone sulfate
(DHEA), total testosterone, total estrogen, and progesterone)
should be near to optimal with physiological cycle (69).
We direct readers to an article by Delaruelle et al. for a
review covering studies investigating the influence of female and
male sex hormones on primary headaches, including migraine
published between 1997 and 2017 (70).
Reproductive milestones
Sex disparities in migraine have been also explained by the
occurrence of reproductive life events, which are linked to
changes in hormone levels. We sorted the included articles
according to these events. Moreover, for an additional and similar
overview of these sex-specific characteristics in individuals with
migraine for an enhanced understanding of the impact of
hormones, we recommend the reviews written by Maleki et al.,
Allais et al., Todd et al., Pakalnis et al. as well as the overview
given by Bronet et al. (22, 71–74). We further recommend the
review by Hipolito Rodrigues, which emphasizes the menopausal
transition (75).
Puberty. Little data are available concerning risk factors for
the onset of migraine in pediatric populations. Therefore,
the association between pubertal timing and migraine was
investigated in a recently published article. Researchers found
that being a woman with an early age of menarche (early
puberty) in a mainly Caucasian population was associated with
a 7% lower odds of migraine at early adulthood - although
pathophysiological links remain to be investigated (76).
Menstruation. The International Classification of Headache
Disorders (ICHD) subdivides menstrual migraine (MM) (with
and without aura) into pure menstrual migraine and menstrually
related migraine, both with and without aura (1). Evidence
regarding the association between migraine and menses has been
further built upon in this review.
A relationship between self-reportedmigraine andmenses has
been reported in almost 60% of women (77). Previous studies
consistently found that MM attacks have a longer duration, are
more challenging to treat and are more impairing (78–82). These
findings have been confirmed by a more recent study of Pavlović
et al., as data from the American Migraine Prevalence and
Prevention (AMPP) Study showed that self-reported migrainous
headache related to menses impacted women to a larger extent.
Also, women with pure menstrual migraine were more impaired
due to the attacks, while women with menstrually related
migraine had the overall highest burden (77). Allodynia, nausea,
vomiting, and phonophobia related to the migraine attacks have
been reported to be more frequent in females with MM as
well (83).
The influence of hormonal changes on the development of
migraine without and with aura is reflected in the results of
a cross-sectional study by Taha et al. Indeed, among females
with migraine, progesterone levels were significantly higher
among those without aura in both phases of the menstrual
cycle (follicular and luteal phase). Estradiol levels showed almost
similar effects in the phases of the cycle. In the luteal phase,
this hormone was significantly higher among females with
migraine without aura, while in the follicular phase, it was
significantly higher among females with mild migraine without
aura. Moreover, a significant increase of prolactin was associated
with an increase in the severity of migraine with and without
aura (84). Interestingly, in the aforementioned translational study
by Ibrahimi et al. (60), relatively low mean estradiol levels were
detected during days 19–21 of the menstrual cycle of the patients
with menstrually related migraine (60).
Conflict in the literature exists concerning pain intensity
and associated symptoms as a result of the fact that these
studies relied on the women’s diagnosis of MM (in a clinical
setting) and possibly suffered from (self-)selection bias (62, 78,
79, 81). Therefore, a prospective study by Vetvik et al. used
records of headache diaries from women with and without a
diagnosis of MM without aura according to the ICHD criteria.
They compared the clinical characteristics of MM and non-
MM without aura attacks in a random sample of women aged
30–34 years with and without MM based on diary assessment.
Results of this study showed that in a representative sample of
females fulfilling the ICHD criteria for MM without aura, MM
without aura attacks had a significantly longer duration and were
more often accompanied by severe nausea than non-MM attacks
without aura. However, in women with migraine without aura
who did not fulfill the ICHD criteria forMM (no diary-confirmed
diagnosis of MM), no significant differences between menstrual
and non-menstrual attacks were found (85).
Moreover, an exploratory study showed that chronic (15
or more days/month for more than 3 months) (1) rather
than episodic migraine might be driving the associations
with menstrual-cycle disorders in general and dysmenorrhea
specifically (86).
Regarding other menstruation-related conditions, our search
strategy retrieved two original articles about endometriosis
with complementary findings. As endometriosis shares
similar characteristics in terms of its clinical manifestations,
epidemiology, and pathogenesis withmigraine, it has been shown
that migrainous headache was more frequent in the women with
endometriosis than in women without endometriosis as well as
in infertile women. Authors of both studies, therefore, suggest
that females with migraine should be screened for endometriosis
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criteria and vice versa, allowing for more individualized
treatment (87, 88).
Pregnancy and breastfeeding. The association between
menstruation and migraine seems to be noticeable during
pregnancy. Indeed, the large, population-based Akershus Birth
Cohort (ABC) Study in Norway showed that pregnant women
with self-reported MM report higher headache intensity during
early pregnancy and directly postpartum compared to women
without self-reported MM. Both groups showed a significant
improvement during the second half of their pregnancies and
directly postpartum. Moreover, the investigators report that
hormonal and menstruation-related factors (premenstrual
syndrome, age at menarche, and the use of hormonal
contraception before pregnancy) showed no association
with headache intensity, except for irregular cycles (89).
The influence of events during pregnancy, including fetal
growth, on the development of migraine during adulthood has
also been investigated. Data from the Norwegian population-
based Nord-Trøndelag Health Study (HUNT 3) showed
significant effect modification by sex in the association between
being born very small for gestational age and the odds ofmigraine
development later in life. This effect was only observed in males,
probably due to differences between both sexes in adaptations
of the fetal-placental unit. Altered activity of neurotransmitters
and/or changes in the brain structure and connectivity might also
be an explanation (90).
Several reviews have been published investigating the
(beneficial) effects of pregnancy on migraine and migraine on
pregnancy, as well as the influence on breastfeeding (91, 92).
Moreover, Parikh describes the expected course of migraine
during pregnancy and the post-partum period as well as
considerations for preventive and abortive medications, although
the latter topic goes beyond the scope of this review (93).
Menopause. Migraine shows variability in the clinical
presentations in the menopausal period, as migraine attacks
might improve, worsen or remain unchanged during this
transition (75). The AMPP study also explored the influence of
the perimenopausal status on the frequency of migraine attacks
in women aged 35–65 years (94). A 1.4-fold increased risk for
high-frequency headache was found during the perimenopause
as compared to the premenopause. This effect might be
confounded or mediated by medication overuse or depression
(94).We recommend a systematic review by Ripa et al. for a more
thorough overview of the articles documenting the relationship
between migraine and menopause (95).
Additional topics
In our search, we also found a case-control study intended to
build further upon the hypothesized role of iron in migraine,
which plays an essential role in the synthesis of serotonin,
dopamine and norepinephrine (96). Accumulation of iron in the
brain, specifically in the deep brain nuclei and the periaqueductal
gray matter, has been shown to be related to the migraine
neurobiology - supported by earlier neuroimaging evidence (97–
100). Results of this study indicated a relationship between
hemoglobin, ferritin, as well as iron-deficiency anemia in subjects
suffering from migraine - mainly women and girls. These
findings suggest that treatment for iron-deficiency anemia or iron
supplementation might be a beneficial preventive method for
patients suffering from migraine coinciding with iron deficiency
anemia. Indeed, both migraine and iron-deficiency (induced by
heavy menstrual flow) are more common in young females (96).
Another study investigating event-related potential among
individuals with migraine without aura in the interictal
period showed that females had more severe abnormalities in
visual neurocognitive processing under attentional conditions
compared to males (101).
Gender Aspects
Migraine characteristics
Besides differences in the presentation of migraine between sexes,
differences between the actual experience or manifestations of
migraine have been previously described, which may be more
related to gender.
A large, longitudinal, internet-based panel study showed that
women reported more frequent attacks and were more likely
to be disabled by their attacks than men (102). According
to this cross-sectional survey, women were significantly more
likely to report that the pain was unilateral and of pounding,
pulsating, or throbbing in nature. Also, symptoms of nausea,
photophobia, phonophobia, osmophobia, and cutaneous ictal
allodynia had been reported significantly more often in women
(102). Additionally, median headache duration of both migraine
with and without aura seems to be longer in women than in
men (103). An age-dependent variation of migraine associated
symptoms (nausea, photophobia, and phonophobia) were only
observed in females with migraine with and without aura, as
significant changes in their frequency were mainly seen after the
age of 30 (103).
Stress and lifestyle
A synergistic relationship between female sex and high levels of
daily stress on risk of migraine headaches has been described.
Females exposed to stress seem to have a higher 1-year prevalence
of migraine, indicating an interplay between biological, sex-
related factors and environmental stress in the progression of
migraine (104).
Lifestyle factors also appear to play a role in migraine.
An inverse relationship between migraine and dietary sodium
intake was described by Pogoda et al. This relationship was
most obvious in females with a lower BMI, while in men,
the relationship did not differ by BMI after confounding
adjustment (105).
Genetics and Biomarkers
There are indications that genetic factors may explain observed
phenotypic sex differences in migraine (20). In their review,
Vetvik and MacGregor discuss that commonly cited genetic
explanations for these differences, such as the disease being
autosomal dominant in women and autosomal recessive in men,
or migraine being a direct consequence of an inherited variant,
might be too simplistic (11). They emphasize that migraine is
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polygenetic, and it is also likely that differences observed between
sexes are also influenced by environmental factors.
At present, a total of 38 genomic variants have been implicated
in migraine risk (106). Only one of these 38 susceptible loci is
located on the X-Chromosome (11).
A link between migraine attack frequency and family history
of migraine was found in males in a cross-sectional study,
suggesting a certain genetic predisposition (107). Furthermore,
an investigation of 12 common migraine risk loci did not find
differences in risks between males or females and across different
migraine subtypes (migraine with and without aura), or clinic-
vs. population settings (108).
Another genotyping study, focusing specifically on the
PRDM16 rs2651899 variant, found a significant difference in this
variant for migraine without aura as well as the female subgroup
compared to controls without migraine in all investigated models
(106). The TRPM8 rs10166942 variant showed an association
with migraine in male subjects and with migraine with aura,
but not in females (106). However, this study had an imbalance
between male and female participants and a rather small sample
size (n= 300) for a genotyping study.
A study investigating the relationship between the
progesterone receptor gene and migraine found that an PGR
polymorphism was not directly connected to predisposition to
migraine, however, it led to a later onset of migraine supposedly
through reduced neuronal excitability in the brain (109).
However, this finding was only observed in females due to the
small number of male participants in the study (109).
Sazci et al. report that previous studies showed an association
between methylenetetrahydrofolate reductase (MTHFR) variants
C677T (rs1801133), A1298C (rs1801131) and migraine (110).
Furthermore, the nicotinamide-N-methyltransferase (NNMT)
variant rs694539, expressed in the brain and other nervous tissue
as a cytoplasmic enzyme, was associated with migraine presence
(110). The implicated MTHFR variants and the NNMT variant
have been linked to higher plasma homocysteine levels, which,
in turn, have been associated with migraine risk (110). However,
the association between the NNMT variant and migraine was
only found in women, with 4.3 times the odds for women with
an AA genotype and the same magnitude of protective effect in
individuals with the G allele (110).
Another genotyping study in a North Indian population (n
= 500) showed a relationship between the rs10156191T variant
and the odds of migraine presence in females (OR = 1.46) as
well as with the odds of having migraine without aura (OR =
1.21) (111). However, due to methodological inconsistencies, the
accuracy of these results is not clear. Still, these findings support
previous hypotheses that diamine oxidase (DAO) increases the
risk of migraine, especially in women (112). Moreover, the
results suggest that the T allele in the same genetic variant
has a protective effect against migraine in men (111). Both
the rs2052129 and rs10156191 variants belong to the DAO
gene, which is associated with high histamine levels, which,
have been implicated in migraine pathophysiology (111). The
presence of the investigated genetic variants is thought to lead
to a reduction of DAO activity (111). Similar findings were
retrieved from Caucasian Spanish (112) as well as North Indian
(111) populations.
Fang et al. investigated the involvement of two specific
genetic variants (rs12134493 and rs2078371), belonging to the
tetraspanin 2 (TSPAN2) gene, in a Han Chinese population (113).
They concluded that rs2078371 could be a potential risk factor
for migraine susceptibility, especially in women and individuals
with migraine without aura, which is similar to results found
previously inWestern populations (113). However, the biological
mechanism of how TSPAN2 variation impacts migraine needs
further exploration (113).
Another genotyping study (114) concentrated on twelve
genetic variants previously reported to be related to migraine
or the metabolism of sex hormones. A variant of rs2229741
was observed more in women with migraine compared to
controls, suggesting a protective association for migraine (114).
Furthermore, the GG genotype of the rs726281 variant, which is
part of the estrogen receptor 1 (ESR1), lowers the susceptibility
for migraine in a subgroup of women with menstrual related
migraine (114). These results were retrieved from a Turkish
population with a rather small sample size (n = 284). A
meta-analysis also found that people with polymorphisms in
two specific exons of the ESR1 (4 325C>G, 8 594G>A)
are more susceptible to migraine, at least in a caucasian
population (115).
In a small genome-wide association study, with 268 cases
and 142 controls, an association between menstrual migraine
and rs2506142 variant, which is located near the neuropilin
1 gene (NRP1), was found (116). The authors conclude that
NRP1 might play a role in the etiology of menstrual migraine.
NRP1 is involved in neuronal development processes in the
nervous and vascular system, as well as in menstruation (116).
It has been shown that activity of NRP1 is increased at the
same time estrogen levels drop in the proliferative phase (116).
Moreover, Sazci et al. report about a relation between that
genetic variant in the SYNE1 and TNF genes and menstrual
migraine (110).
So far, findings suggest that there might be a certain overall
genetic predisposition for migraine presence. However, there are
no clear differences in the association pattern between sexes.
Some studies only showed significant associations of identified
single genetic variants or genetic risk scores for one sex, mainly
females. But due to the imbalances in sex distribution and partly
small sample size of some studies, these findings should be
interpreted with great caution. It is suspected that additional
endogenous or exogenous factors may explain this difference
(11). In the comparison between male and female migraine cases,
it seems more likely that migraine has a stronger genetic basis
among men than women (108). Still, Nyholt et al. report that
differences in genetic risks in the subgroups are outweighed
by similarities, suggesting that further investigation is needed.
Thus, epigenetics came into the focus of attention, concentrating
on interactions between different genetic predispositions and
environmental influences (20).
There has also been research activity in the field of
biomarkers, however, not very recently. In a review by Tietjen
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and Khubchandani (117) articles investigating the connection
between various vascular biomarkers and migraine were
identified (129 citations). It was reported that some studies found
elevated CRP levels in female subgroups with migraine; however,
the results about CRP and migraine were very inconsistent. For
other biomarkers, either no sex difference was found, such as in
adiponectin levels, or no sex differences were mentioned at all.
If results referred to women only, the study was conducted in an
exclusively female study population, thus no conclusion about sex
differences could be made (117).
Neuroimaging
The study of brain imaging contributes to an enhanced
understanding of the pathophysiology of migraine, as functional,
chemical, and structural differences between males and females
with migraine have been observed (20, 71). Surprisingly, our
search strategy only retrieved reviews, but no original articles.
The review by Maleki and Androulakis explains neuroimaging
patterns that distinguish females from males in migraine, also in
relation to sex-related influences. Moreover, the authors mention
the influence of neuroimaging in the light of some earlier
described specific life events, including the perimenopause,
estradiol decline and puberal phase (71). In addition, Chong
et al. provide an overview of studies concerning sex difference
published in the period between January 2012 and 2016 (118).
Previous functionalMRI studies have shown that the posterior
insular cortex and the precuneus are thicker in females compared
to males with migraine (7). Also, a smaller volume of the
parahippocampal gyrus was observed in these males. Moreover,
female sex has been related to lower gray matter in the right
dorsolateral prefrontal cortex (119).
These imaging studies also seem to explain the attribution
of gender aspects in migraine, as they show gender-related
differences in the involvement of regions which govern the
emotional aspects of pain. Indeed, the possible involvement of the
hippocampus, though not yet established, might explain gender
(and sex) differences in behavioral responses to the stress and
explain differences in migraine attack (20).
As highlighted by Schroeder et al. and Pavlovic et al., the
majority of the neuroimaging studies have included mainly
females with migraine (14, 15). Lastly, there exist very limited
neuroimaging studies with considerably small sample sizes that
have examined sex-related differences in migraine (71).
DISCUSSION
In this review, we systematically searched literature exploring sex
and gender differences in migraine in the areas of epidemiology,
basic science, clinical science, genetics, and neuroimaging and
have summarized the findings.
Migraine is a highly prevalent and burdensome disease,
particularly among women. Still, the disease is responsible
for a great share of disability in both sexes. Distributional
differences in gender-related lifestyle factors such as marital
status, employment, and social support have also been observed
among persons suffering from migraine. While many biological
factors have been hypothesized to play a role in the sex difference,
particularly sex hormones or sex hormonal fluctuations, a clear
understanding of why migraine is different between women
and men remains illusive. Many studies from which we extracted
results lacked a clear operationalization of sex and gender,
even when sex and/or gender aspects were the main focus of
the research. Further complicating the evidence synthesis, the
majority of studies presenting prevalence do not consistently use
either lifetime prevalence or 1-year attack prevalence, making
them difficult to compare. Other studies lack any specification of
a time frame, which is indispensable for a correct interpretation
of the results.
From a pathophysiological point of view, the influence of sex
differences related to hormone levels on a variety of mechanisms
(including the role of CGRP, cortical spreading depression,
and various anti- and proinflammatory mediators) involved in
migraine have primarily been studied in animals and often in
isolation, as no experimental model of migraine covers all aspects
of this disorder. This may be a limitation, since these processes
are interrelated and are known to influence each other. Little
research regarding gender roles can be conducted on a basic
sciences level; however, some important behavior-related aspects
have been explored. Translational studies on the topic include
human studies exploring trigeminovascular reactivity in a non-
invasive manner.
The majority of articles identified in this review consisted of
clinical studies and reviews. Clearly, sex hormones (including
estrogen, progesterone and testosterone) contribute prominently
to the observed sex-related differences. Specifically, changes in
the migraine phenotype (including the amount of attacks and
intensity) attributable to female-specific reproductive milestones
highlight the profound effects of these sex aspects, with migraine
becoming more prevalent in women starting in puberty, peaking
in their thirties, and steeply declining after menopause. The
clinical studies indicate that gender-related aspects are also
important to consider, as males and females might have different
pain perceptions and experiences. Reporting bias in clinical
studies should not be overlooked, as the evidence indicates
males more often underreport their symptoms, which likely
contributes to a continued underrepresentation in clinical (and
epidemiological) studies.
In the genetics literature, specific variants have been found
to be associated with certain migraine subtypes, such as
migraine with aura in both sexes or menstrual migraine in
women, as well as the presence of migraine in females. Certain
genetic variants (rs2651899, rs694539, rs10156191, rs2078371,
rs2506142) appear to make individuals more susceptible to
ever having migraine. Though genetics may provide useful
mechanistic insights, the individual studies acknowledge that
genetic aspects alone do not provide a full explanation for the sex
differences observed in this multifactorial disease. In addition,
as men were underrepresented in these studies and some had
small sample sizes, their conclusions should be interpreted
with caution.
Surprisingly, in the field of research about biomarkers and
migraine, beyond the articles included in one review from 2015
(117), we did not identify any new articles in this area. Lastly,
we only found reviews and no original articles on neuroimaging
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describing sex- and gender related differences, highlighting
another gap in the existing literature.
Strengths and Limitations
This review has several strengths. First, unlike several narrative
reviews on this topic, we developed an extensive, systematic
search strategy and employed a rigorous inclusion and screening
in an effort to systematically identify all recent relevant articles.
We hope the thorough description of the searching steps
and access to the developed search strings contribute to the
transparency and reproducibility of our method. We synthesized
newly published evidence in the context of the main findings of
previously published review articles in an effort to provide broad
topical coverage while minimizing unnecessary redundancy.
Furthermore, we made an effort to go beyond biological sex
aspects and also include gender aspects (behaviors, roles, etc.)
where available. In an attempt to convey the distinction between
both concepts, in our synthesis, we attempted to consistently
operationalize sex as biological differences and gender as social
construct that is shaped by cultures and varies over time. This
approach stands in contrast to previous reviews and much of
the original literature, in which the terms “sex” and “gender” are
often used interchangeably.
Some limitations should be considered in the interpretation
of our results. First, this review is limited by the articles we
found through our search strategy. To limit extensive overlap
with previous reviews and focus on the newest literature (2015-
present), older studies were summarized more broadly based on
existing reviews (11, 14, 15, 20, 22, 43, 54, 56, 58, 70–75, 91–
93, 95, 117, 118). Second, we excluded articles investigating the
effects of migraine therapies and treatments to focus on sex- and
gender-differences in migraine as a disease, itself, rather than
sex-specific differences related to individual treatment strategies,
adherence, and migraine management. We acknowledge there
are important (behavioral) differences betweenmales and females
with respect to treatment, but these are outside the scope of the
present review (102, 120). Robbins and Bernat did not identify
articles on treatment efficacy stratified by sex, illustrating that
this topic also needs more attention in the field of migraine
treatment research (121). Sex and gender differences in migraine
comorbidities were also outside the scope of our review.
Finally, we did not provide a rigorous quality assessment
of the included articles, though we made an effort to caution
against over-interpretation, especially where the evidence was
particularly thin. Given these aforementioned limitations, we do
not claim that this review is exhaustive in terms of findings in
the field of sex and gender differences in migraine, however, we
believe it is quite comprehensive given its scope.
Recommendations
Taking the above-mentioned gaps into account, we encourage
further studies on sex and gender aspects in migraine across
all relevant basic, clinical and population science domains and
advocate for clearer operationalization of both terms - sex and
gender - in future work.
Second, we observed that most studies did not contain a
primary objective to identify sex- and/or gender differences.
These differences were rather stated as secondary findings,
implying that some studies may not have been sufficiently
powered to detect differences between sex or gender strata.
We advocate for a priori consideration of relevant research
questions pertaining to sex and/or gender and investigation
of sex and/or gender as a potential effect measure modifier.
Furthermore, many studies matched participants with and
withoutmigraine by sex (or gender) to answer the study’s primary
research question, which makes inferences about the relationship
between sex (or gender) and migraine impossible by design.
This highlights a large methodological issue pervasive in the
included literature: authors often matched for sex and provided
averaged estimates, even though sex and gender differences are
well-known. Therefore, a point of improvement for future studies
is to avoid averaging of the effect size across of both sexes and/or
genders, or to at least additionally provide stratified estimates.
Third, we echo the comments of other authors (11,
117) encouraging further research to include diverse study
populations. In our review, we were explicit in our aims
to identify new findings in transgender or intersex people
and included these terms in the search strategy. To date, we
found only two studies (122, 123) that investigated migraine in
transgender people. This highlights sex and gender diversity as
an insufficiently studied area in migraine research.
Fourth, basic science studies with a more representative
distribution of sexes are warranted. Indeed, female animals
are often underrepresented in animal studies. Although it may
be justified to constrain the experimental animal population
to one sex (or a specific age) for some research questions,
it is a common misunderstanding that the inclusion of only
male animals will lead to more reproducible results with less
variation. While results of animal experiments in females may
be affected by their estrous cycle and may thus be subject to
intraindividual variation over time, experiments in male animals
may likewise exhibit such variations for other reasons such
as differences between dominant and subordinate males when
housed together (124). Although most included basic science
articles used a balanced distribution of males and females, there
is still considerable room for improvement. Similar issues also
arise in human studies, where only a few studies investigated
migraine in males. As mentioned in the review by Schroeder et al.
(15), societal differences and stigma surrounding this “feminized”
disease should not be underestimated.
Fifth, we noticed potential for improvement in
methodological quality and reporting across the included
articles. In the first stage of the screening process, we were
forced to exclude several articles due to methodological issues.
Furthermore, in the presentation of the results, it was often
difficult to discern whether the described methods were actually
(and correctly) applied. Many articles reported conclusions that
did not align with their stated aims, were overstated, or did not
reasonably reflect their results.
Sixth, we encourage translational research of sex and gender
across the three pillars - basic, clinical, and epidemiological
studies - of the broad field of medicine. Although we identified
existing translational research (“from benchside to bedside”), no
articles assessed translational aspects from benchside to clinic
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or population level. Perhaps unsurprisingly, gender aspects were
more often thematized in epidemiological studies, whereas sex
aspects were addressed more frequently in basic science. Clinical
articles showed fluidity of these domains and contained both
aspects. Although the study of gender aspects in basic science
might be challenging, behavioral animal studies might be an
interesting area for further exploration.
Lastly, we recommend the adoption of a more holistic and
interdisciplinary approach to understanding sex and gender
differences in migraine across the different domains. Genetics
and biomarkers alone have not provided a conclusive answer in
explaining the observed sex and gender differences, and further
work is needed to explore possible important intersections
between genetics, pathophysiology, behavior and environment.
CONCLUSION
A thorough understanding of sex and gender differences in
migraine provides important insights into the pathophysiological
processes involved in migraine as well as implications on
a population level. Though research into these aspects in
the domains of epidemiology, basic science, clinical research,
genetics, and neuroimaging continues, several observed sex and
gender differences remain unexplored. Therefore, future studies
in migraine research should prioritize sex and gender aspects,
consider using consistent definitions of these concepts, and
employ suitable methods to explore these relevant differences
instead of controlling for them.
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